TGTatiana A. Giovannucci

Tatiana A. Giovannucci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatiana A. Giovannucci has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue

    by Aram Aslanyan, Soumya Mukherjee, Eleanor M. Moncur, Alicja Szadziewska, Yingxin He, Przemysław R. Kac, Reid Coyle, Elena Camporesi, Chihiro Sato, Nupur Ghoshal, et al.

    Alzheimer disease begins in the brain many years before symptoms, but early changes are usually studied after death or indirectly through fluid and imaging biomarkers. Here we show that small brain biopsies collected during ventriculoperitoneal shunt surgery can be used to study Alzheimer disease pathology and protein turnover during life. We analysed biopsies from 18 individuals with suspected normal pressure hydrocephalus, alongside matched ventricular and lumbar cerebrospinal fluid and post-mortem control brain tissue. Amyloid plaques were present in 9 of 18 biopsies, while mature tau tangles were rare. Matrix-assisted laser desorption/ionization mass spectrometry imaging mapped amyloid plaque chemistry within tissue. Phosphorylated tau 217 was enriched around plaques, supporting a local relationship between amyloid and tau pathology. Stable isotope labelling, which tracks newly made proteins, detected rapid tau labelling within approximately 3 hours and estimated brain tau half-life at about 34 days. Amyloid plaques showed little detectable turnover.


  • Open Access

    CSF protein clearance impairment revealed using stable isotope kinetics in normal pressure hydrocephalus

    by Claire A Leckey, Tatiana A Giovannucci, Eimear C Murphy, Eleanor M Moncur, Kanza Tariq, Aram Aslanyan, Michael Schöll, Meera Srikrishna, William Coath, Suzanne Barker, et al.

    Normal pressure hydrocephalus is a common cause of gait and cognitive impairment in older adults, marked by excessive CSF accumulation. Genetic studies suggest impaired fluid clearance, and clinical symptoms can improve after CSF diversion. However, no fluid biomarkers exist to explore CSF accumulation mechanisms, assist diagnosis, or predict response to treatment. Stable isotope labelling kinetics is a clinical research tool that uses non-radioactive isotopes to label newly translated proteins, enabling measurement of their appearance (synthesis) and disappearance (clearance) in compartments like CSF. This study aimed to develop a novel method to capture protein turnover in CSF and assess whether clearance disruption is evident in normal pressure hydrocephalus with extended follow-up. Proteins of interest were identified via mass spectrometry in human CSF and choroid plexus organoid-derived CSF-like fluid. Protein origin and synthesis rates were evaluated by labelling organoids with 13C6-leucine. Label incorporation was measured using targeted mass spectrometry to determine the ratio of labelled to unlabelled peptide. A proof-of-concept case-control study was then conducted in specialist neuroscience centres. Participants received intravenous 13C6-leucine and underwent serial CSF withdrawal via lumbar drain, with matched blood sampling for up to 72 h. Patients undergoing CSF drainage and controls were recruited sequentially. Targeted mass spectrometry was used to determine protein production and clearance rates. To determine the clinical relevance of these protein turnover rates to CSF flow, they were correlated with direct measurements of CSF production captured using a LiquoGuard machine linked to the lumbar CSF drain. We captured choroid plexus protein kinetics in human organoids and the CSF of participants undergoing CSF drainage (n = 10) or controls (ventricular CSF n = 4; lumbar CSF n = 5). The case and control cohorts varied in sex (NPH = 80% male and controls = 22% male) and in age. There was no significant age difference between NPH and the lumbar control cohort (n = 5) (NPH: 75 (71–78) versus 70 (63–84) years old; P = 0.2438). We found that transthyretin is abundantly secreted by choroid plexus organoids, and observed correlations with CSF transthyretin synthesis rates and volume of CSF production in vivo (P = 0.738; P < 0.05). Clearance rates of transthyretin are ∼10 fold slower in normal pressure hydrocephalus compared with controls, suggesting impaired CSF protein clearance. This method is a novel clinical tool for interrogating CSF protein dynamics and may have utility in tracking CSF flow clinically.


  • Open Access

    Stable isotope labelling kinetics of neurofilament light

    by Claire A Leckey, Tatiana A Giovannucci, John B Coulton, Yingxin He, Chihiro Sato, Nupur Ghoshal, Tharini Vignarajah, Zane Jaunmuktane, Nicolas R Barthélemy, Henrik Zetterberg, et al.

    This study provides the first quantification of neurofilament light chain (NfL) kinetics in the human CNS using stable isotope labelling kinetics. NfL is elevated in CSF and blood across a range of traumatic, inflammatory and neurodegenerative diseases of the CNS, and has been increasingly included in clinical trials as a secondary or exploratory outcome measure of target engagement. Interpreting trajectories of NfL post-treatment has been challenging, prompting a greater need and focus on understanding its pathophysiology. We set out to measure NfL kinetics in the human CNS using stable isotope labelling kinetics. In human neurons derived from induced pluripotent stem cells, we show that NfL turnover is relatively slow, comparable to other long-lived proteins such as tau. We detected a delay of 3 to 6 days in the release of NfL into the media, unexpected for a passively released protein and supporting that controlled mechanisms of release could contribute to the appearance of NfL in the extracellular milieu. We optimized the kinetic NfL assay to measure the turnover of NfL in the human CNS. Participants with diagnosed primary tauopathies (n = 10) were recruited to the Human CNS Tau Kinetics in Tauopathies study and a cohort of cognitively unimpaired or with mild cognitive impairment (Clinical Dementia Rating score ≤0.5; n = 22) to the Tau Stable Isotope Labelling Kinetics study. Patients with suspected normal pressure hydrocephalus (n = 3) and primary tauopathy cases (n = 3) were examined to assess labelling in the brain parenchyma and ventricular CSF. In brain tissue, isotopically labelled in vivo and sampled ex-vivo and post-mortem, NfL is rapidly labelled but remains stable 18 months after, indicating very slow turnover and likely incorporation into very stable NfL networks. In line with a controlled mechanism of release in vivo, appearance of labelled NfL in CSF was detectable between 53 and 162 days post-labelling, during which NfL labelling did not reach its peak, suggestive of a half-life in CSF >3 months. These findings support the interpretation that acute rises in CSF NfL concentration are likely to be related to passive release or CSF clearance failure. We also show that active but delayed release of newly translated NfL can contribute to the concentration of NfL in CSF, but this would not be expected for at least 8 weeks. Clinical trials using NfL as an outcome measure will benefit from substantially longer follow-up periods and isotopic labelling to understand the NfL response to therapeutic intervention.


  • Open Access

    Independent Generation of Amyloid-β via Novel APP Transcripts

    by Emil K. Gustavsson, Emily Abel, Hannah Macpherson, Gunnar Brinkmalm, Diana Piotrowska, Aaron Z. Wagen, Kylie Montgomery, Claudio Villegas-Llerena, Tatiana A. Giovannucci, Rohan de Silva, et al.

    The amyloid precursor protein ( APP ) is processed by multiple enzymes to generate biologically active peptides, including amyloid-β (Aβ), which aggregates to form the hallmark pathology of Alzheimer’s disease (AD). Aβ is produced through an initial β-secretase cleavage of APP, generating a 99-amino acid C-terminal fragment (APP-C99). Subsequent cleavage of APP-C99 by γ-secretase produces Aβ peptides of varying lengths. To better understand the transcriptional regulation of Aβ production, we employed long-read RNA sequencing and identified previously unannotated transcripts encoding APP-C99 with an additional methionine residue (APP-C100), generated independently of β-secretase cleavage. These transcripts are expressed separately from full-length APP , and we observed that cells lacking full-length APP can still produce Aβ through these shorter isoforms. Importantly, mass spectrometry analysis of cerebrospinal fluid (CSF) revealed peptides consistent with the methionine-extended Aβ species, supporting the in vivo translation of these transcripts. Our findings reveal an alternative pathway for Aβ generation and aggregation, highlighting a potential new target for modulating Aβ accumulation in AD.


  • Navigating uncertainty: A tripartite creative knowledge exchange among artists, researchers and people with lived experience of dementia – A co-created space for living uncertainty

    by Mar Estarellas, Tatiana A. Giovannucci, Lucy Steggals

    In a world increasingly shaped by uncertainty, Ebb & Flow emerged as a convergence of dementia research, caregiving and artistic practice within a collaborative knowledge exchange. This article examines how uncertainty is experienced and navigated through an interdisciplinary project involving artists, researchers, carers and individuals living with dementia. Developed under the Trellis:Arbor programme at the University College London, Ebb & Flow fostered a creative and inclusive ‘humanspace’ to explore uncertainty, metaphorically guided by the unpredictability of the sea. Over three months, participants used art, writing, digital mediums and co-created resources like a digital logbook and the Ebb & Flow card deck, promoting dialogue, empathy and resilience. The project culminated in a public exhibition showcasing shared experiences and artistic outcomes. Findings highlight that integrating artistic methods into dementia care and research environments significantly enriches empathy, adaptability and collective understanding, demonstrating the transformative potential of embracing uncertainty collaboratively.

  • Open Access

    Cerebrospinal fluid clearance impairment captured using stable isotope labeling kinetics (SILK) in normal pressure hydrocephalus

    by Ca Leckey, Ta Giovannucci, Ec Murphy, E Moncur, K Tariq, A Aslanyan, M S Scholl, M Srikrishna, W Coath, S Barker, et al.

    Normal pressure hydrocephalus is a common cause of gait and cognitive impairment in later life, characterised by accumulation of excessive cerebrospinal fluid (CSF). Clinical improvement can occur following CSF diversion. No biomarkers are available to mechanistically investigate fluid accumulation, support diagnosis or predict response to CSF diversion. We developed a stable isotope labeling kinetics (SILK) method to capture the function of the main site of production of CSF in humans, the choroid plexus (ChP), in vitro and in vivo . We captured ChP protein kinetics in human ChP organoids and the CSF of participants with suspected NPH undergoing CSF drainage (n=10) or controls (n=9). We found that transthyretin is abundantly secreted by ChP organoids, and we observe correlations with CSF transthyretin synthesis rates and volume of CSF production in vivo (ρ=0.738; pOne Sentence Summary: Using stable isotope labeling kinetics of choroid plexus proteins, in human choroid plexus organoids and in vivo, we find that synthesis and clearance of transthyretin is altered in normal pressure hydrocephalus.

  • Open Access

    Stable isotope labeling kinetics of neurofilament light in vitro and in vivo

    by Claire A. Leckey, Tatiana A. Giovannucci, John B. Coulton, Yingxin He, Chihiro Sato, Nupur Ghoshal, Tharini Vignarajah, Zane Jaunmuktane, Nicolas R. Barthélemy, Henrik Zetterberg, et al.

    Importance: Neurofilament light (NfL) is elevated in CSF and blood across a range of traumatic, inflammatory and neurodegenerative diseases of the central nervous system, and has been increasingly included in clinical trials as an outcome measure of target engagement. Interpreting trajectories of NfL post-treatment has been challenging, prompting a greater need and focus on understanding its pathophysiology. Objective: We measured NfL kinetics in the human central nervous system using stable isotope labeling kinetics (SILK). Design: Observational study. Participants underwent SILK protocol. Infusion of 16 hours with 4mg/kg/h and follow-up lumbar punctures scheduled at 7, 14, 60 and 120 days post-labeling. Setting: Referral center – specialist neurology clinic. Participants: Participants with diagnosed primary tauopathies (n=10) were recruited to the Human CNS Tau Kinetics in Tauopathies (TANGLES) study. A control case was examined post-mortem to assess the technical background of the SILK method. Exposure: Intravenous infusion of 13 C 6 -leucine, with rates of label incorporation representative of fractional synthesis and fractional clearance rates in vivo and in vitro . Main outcome and Measure: Level of incorporation of 13 C 6 -leucine tracer into newly-translated NfL divided by the pool of NfL with previously incorporated 12 C 6 -leucine, expressed as a percentage tracer-to-tracee (TTR) ratio. Results: NfL is rapidly translated in human brain within hours but takes 53 – 162 days to appear in cerebrospinal fluid (CSF). Labeled NfL remains detectable in post-mortem brain tissue 1.5 years post-labeling, indicating an extremely slow turnover in the human CNS. Together, these data suggest the greatest contribution of CSF NfL in neurodegeneration is from slow release of a large pool of previously translated NfL. However, release of newly translated NfL makes a significant contribution. Conclusion and relevance: Rapid increases in CSF NfL seen within weeks of disease processes or interventions are likely to reflect release of pre-existing NfL from damaged neurons, but later increases in NfL (>3 months) may also reflect new NfL translation and release. Clinical trials using NfL as an outcome measure to track neurodegeneration would particularly benefit from substantially longer follow-up periods due to the slow turnover of the protein in the central nervous system.


  • Open Access

    CSF neurofilament light chain profiling and quantitation in neurological diseases

    by Claire A Leckey, John B Coulton, Tatiana A Giovannucci, Yingxin He, Aram Aslanyan, Rhiannon Laban, Amanda Heslegrave, Ivan Doykov, Francesca Ammoscato, Jeremy Chataway, et al.

    Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid diagnosis and monitor progression and as an outcome measure to assess safety and efficacy of disease-modifying therapies across the clinical translational neuroscience field. Quantitative methods for neurofilament light chain in human biofluids have relied on immunoassays, which have limited capacity to describe the structure of the protein in CSF and how this might vary in different neurodegenerative diseases. In this study, we characterized and quantified neurofilament light chain species in CSF across neurodegenerative and neuroinflammatory diseases and healthy controls using targeted mass spectrometry. We show that the quantitative immunoprecipitation–tandem mass spectrometry method developed in this study strongly correlates to single-molecule array measurements in CSF across the broad spectrum of neurodegenerative diseases and was replicable across mass spectrometry methods and centres. In summary, we have created an accurate and cost-effective assay for measuring a key biomarker in translational neuroscience research and clinical practice, which can be easily multiplexed and translated into clinical laboratories for the screening and monitoring of neurodegenerative disease or acute brain injury.


  • Open Access

    Stable Isotope Labelling Kinetics tracing of Neurofilament Light in stem cell‐derived neurons and humans

    by Tatiana A. Giovannucci, Claire A. Leckey, John Coulton, Henrik Zetterberg, Donald L Elbert, Randall J. Bateman, Kevin Mills, Selina Wray, Ross W. Paterson

    Background: Neurofilament light (NfL) is a neuronal cytoskeletal protein that is released into the extracellular environment from degenerated axons. As such, NfL levels in cerebrospinal fluid (CSF) and serum have been proposed as a promising biomarker of neurodegeneration, yet the metabolism of NfL in human neurons is unknown. Kinetic protein labelling can provide protein half‐lives and rates of production and clearance in vitro and in vivo.Method: Using a stable isotope tracer (13C6‐leucine), we labelled two lines of pluripotent stem cell‐derived neurons and human study participants with primary tauopathies (n = 9). We collected neuronal lysates and conditioned media every three days during the labelling (“pulse”) and post‐labelling (“chase”) phases. CSF samples were collected across five visits, scheduled around 4, 14, 20, 60 and 120 days post‐labelling. We measured the ratio of labelled to unlabelled NfL using targeted mass spectrometry workflows to quantitate the rates of protein labelling (fractional synthesis rate) and label loss (fractional clearance rate), together providing the protein turnover rate.Result: The average half‐life of NfL in cell lysates was four days (± 1.06 SD, n = 3 independent biological replicates). The turnover of extracellular NfL in neuronal conditioned media was slower than that found in neuronal lysates, suggesting that NfL is a rather stable protein in the extracellular milieu in vitro. In contrast, analysis of CSF from the in vivo tauopathy cohort detected low labelling of NfL (0.04 – 0.36%) by 120 days (n = 5), indicating that in vivo turnover is exceptionally slower than in vitro and that extended CSF collection and analysis >120 days post‐labelling is crucial to capture NfL production and clearance in vivo. To this end, additional analysis of healthy controls and patients with Alzheimer’s disease (control and AD cohorts; n = 24), which include CSF collection up to 219 ‐ 444 days post‐labelling, is ongoing.Conclusion: Tracking of both intracellular and extracellular NfL in neurons derived from healthy control individuals, as well as cells with mutations implicated in neurodegenerative diseases, are expected to shed light into the dynamics of NfL turnover in both physiological and pathological conditions. This will be critical for interpreting NfL in response to disease‐modifying therapies.

  • Open Access

    Identification of a novel compound that simultaneously impairs the ubiquitin-proteasome system and autophagy

    by Tatiana A. Giovannucci, Florian A. Salomons, Henriette Stoy, Laura K. Herzog, Shanshan Xu, Weixing Qian, Lara G. Merino, Maria E. Gierisch, Martin Haraldsson, Alf H. Lystad, et al.

    The ubiquitin-proteasome system (UPS) and macroautophagy/autophagy are the main proteolytic systems in eukaryotic cells for preserving protein homeostasis, i.e., proteostasis. By facilitating the timely destruction of aberrant proteins, these complementary pathways keep the intracellular environment free of inherently toxic protein aggregates. Chemical interference with the UPS or autophagy has emerged as a viable strategy for therapeutically targeting malignant cells which, owing to their hyperactive state, heavily rely on the sanitizing activity of these proteolytic systems. Here, we report on the discovery of CBK79, a novel compound that impairs both protein degradation by the UPS and autophagy. While CBK79 was identified in a high-content screen for drug-like molecules that inhibit the UPS, subsequent analysis revealed that this compound also compromises autophagic degradation of long-lived proteins. We show that CBK79 induces non-canonical lipidation of MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3 beta) that requires ATG16L1 but is independent of the ULK1 (unc-51 like autophagy activating kinase 1) and class III phosphatidylinositol 3-kinase (PtdIns3K) complexes. Thermal preconditioning of cells prevented CBK79-induced UPS impairment but failed to restore autophagy, indicating that activation of stress responses does not allow cells to bypass the inhibitory effect of CBK79 on autophagy. The identification of a small molecule that simultaneously impairs the two main proteolytic systems for protein quality control provides a starting point for the development of a novel class of proteostasis-targeting drugs.